Glycomark®, Inc. Partners With Shiel Medical Laboratory To Expand Glycomark Test In The Northeast

Share Article

GlycoMark, Inc. announced today a partnership with Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast. This agreement facilitates greater accessibility for patients and clinicians.

“There is a surge of momentum for the GlycoMark test as more healthcare professionals, hospitals, and universities—both in the U.S. and internationally—recognize the utility of GlycoMark to indicate recent hyperglycemic episodes and glycemic variability,”

GlycoMark, Inc. announced today a partnership with Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S.

GlycoMark is the only clinically available blood test that specifically indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related to post prandial glucose peaks.

“There is a surge of momentum for the GlycoMark test as more healthcare professionals, hospitals, and universities—both in the U.S. and internationally—recognize the utility of GlycoMark to indicate recent hyperglycemic episodes and glycemic variability,” said Hirotaka “Hiro” Ishibashi, COO of GlycoMark, Inc. “GlycoMark offers insight into hyperglycemia that traditional tests reflecting mean glucose levels, such as A1C, cannot.”

The agreement with Shiel Medical Laboratory provides even broader access to the GlycoMark test as it possesses a significant regional presence in the states of New York and New Jersey, and has now expanded into the Connecticut and Pennsylvania markets.

ABOUT GLYCOMARK
The GlycoMark test is a CE-marked and FDA cleared test that provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma, for intermediate-term monitoring of glycemic control in people with diabetes. The test is for professional use, and is not intended to diagnose or prevent any specific diabetes state or disease. Since its discovery, 1,5-AG has been described in more than 600 scientific and medical publications. GlycoMark, Inc. is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan) and Nippon Kayaku Co., Ltd. (Tokyo, Japan) and is dedicated to the discovery and commercialization of novel biomarkers for diabetes. Visit http://www.glycomark.com.

ABOUT SHIEL MEDICAL LABORATORY
Founded in 1919, Shiel Medical Laboratory is one of the oldest continuously operating clinical laboratories in the United States, and the largest privately held laboratory in New York. Shiel maintains a significant regional presence in New York and New Jersey, and has now expanded into the Connecticut and Pennsylvania markets. The laboratory currently services Private Physicians, Group Practices, Union and Industrial Accounts, Long-Term Care Facilities, Home Care Agencies and Clinical Trials.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jill Willie
800 Meters
+1 504-432-6730
Email >
GlycoMark
since: 01/2013
Like >
Visit website